RNASET2 and cancer: Human recombinant RNASET2 treatment of nude mice injected with HT29 or A3775SM human cancer cells was associated with a three-fold decrease in tumor volume compared to Avastin-treated animals, coupled with a significant decrease in mean blood vessel counts and higher survival rates [108].